Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications

Lancet Infectious Diseases

Volumn 6, Issue 11, 2006, Pages 699-709

  Gerrits, Monique M ^a   van Vliet, Arnoud HM ^a   Kuipers, Ernst J ^a   Kusters, Johannes G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISMUTH; BISMUTH CITRATE; BISMUTH SALICYLATE; CHOLERA TOXIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; FURAZOLIDONE; LANSOPRAZOLE; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MOXIFLOXACIN; NITROFURAN; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PENICILLIN G; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RANITIDINE BISMUTH CITRATE; RIFABUTIN; RIFAMYCIN; TETRACYCLINE; TINIDAZOLE; UNINDEXED DRUG; VACUOLATING TOXIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM CULTURE; CANCER RISK; CARCINOGENESIS; DRUG MECHANISM; GASTRODUODENAL ULCER; HELICOBACTER PYLORI; HUMAN; IN VIVO CULTURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STOMACH ULCER;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

EID: 33750148431     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(06)70627-2     Document Type: Review

References (148)

1. Warren J., and Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1 (1983) 1273-1275
2. Marshall B., and Warren J. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1 (1984) 1311-1315
3. Marshall B., Armstrong J., McGechie D., and Glancy R. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 142 (1985) 436-439
4. Morris A., and Nicholson G. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82 (1987) 192-199
5. Kusters J., van Vliet A., and Kuipers E. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 19 (2006) 449-490
6. Suerbaum S., and Michetti P. Helicobacter pylori infection. N Engl J Med 347 (2002) 1175-1186
7. Frenck Jr. R., and Clemens J. Helicobacter in the developing world. Microbes Infect 5 (2003) 705-713
8. Rothenbacher D., and Brenner H. Burden of Helicobacter pylori and H pylori-related diseases in developed countries: recent developments and future implications. Microbes Infect 5 (2003) 693-703
9. Genta R. Review article: after gastritis-an imaginary journey into a helicobacter-free world. Aliment Pharmacol Ther 16 suppl 4 (2002) 89-94
10. Versalovic J. Helicobacter pylori. Pathology and diagnostic strategies. Am J Clin Pathol 119 (2003) 403-412
11. Ong S., and Duggan A. Eradication of Helicobacter pylori in clinical situations. Clin Exp Med 4 (2004) 30-38
12. Prince M., Osborne J., Ingoe L., Jones D., Cobden I., and Barton J. The CLO test in the UK: inappropriate reading and missed results. Eur J Gastroenterol Hepatol 11 (1999) 1251-1254
13. MacOni G., Vago L., Galletta G., et al. Is routine histological evaluation an accurate test for Helicobacter pylori infection?. Aliment Pharmacol Ther 13 (1999) 327-331
14. Moayyedi P., and Dixon M. Any role left for invasive tests? Histology in clinical practice. Gut 43 suppl 1 (1998) S51-S55
15. Ford A., Qume M., Moayyedi P., et al. Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 128 (2005) 1838-1844
16. Gisbert J., and Pajares J. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection-a critical review. Aliment Pharmacol Ther 20 (2004) 1001-1017
17. Fallone C., Loo V., and Barkun A. Utility of serology in determining Helicobacter pylori eradication after therapy. Can J Gastroenterol 12 (1998) 117-124
18. Bayerdorffer E., Neubauer A., Rudolph B., et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 345 (1995) 1591-1594
19. Sugiyama T., Sakaki N., Kozawa H., et al. Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther 16 suppl 2 (2002) 187-190
20. McNulty C., Dent J., and Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother 28 (1985) 837-838
21. Graham D. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 115 (1998) 1272-1277
22. McNulty C., Dent J., Ford G., and Wilkinson S. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 22 (1988) 729-738
23. van Zanten S., Goldie J., Hollingsworth J., Silletti C., Richardson H., and Hunt R. Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol 45 (1992) 225-227
24. Grayson M., Eliopoulos G., Ferraro M., and Moellering Jr. R. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 8 (1989) 888-889
25. Debets-Ossenkopp Y., Namavar F., and MacLaren D. Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents. Eur J Clin Microbiol Infect Dis 14 (1995) 353-355
26. Megraud F., and Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 17 (2003) 1333-1343
27. Gisbert J., and Pajares J. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 10 (2005) 363-372
28. Damianos A., and McGarrity T. Treatment strategies for Helicobacter pylori infection. Am Fam Physician 55 (1997) 2765-2774
29. van der Hulst R., Keller J., Rauws E., and Tytgat G. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1 (1996) 6-19
30. Spengler G., Molnar A., Klausz G., et al. Inhibitory action of a new proton pump inhibitor, trifluoromethyl ketone derivative, against the motility of clarithromycin-susceptible and-resistant Helicobacter pylori. Int J Antimicrob Agents 23 (2004) 631-633
31. Borody T., Andrews P., Fracchia G., Brandl S., Shortis N., and Bae H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 37 (1995) 477-481
32. Graham D., Hammoud F., El-Zimaity H., Kim J., Osato M., and El-Serag H. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 17 (2003) 1229-1236
33. Chiba N. Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens. Can J Gastroenterol 14 (2000) 885-889
34. Lambert J., and Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 11 suppl 1 (1997) 27-33
35. Gorbach S. Bismuth therapy in gastrointestinal diseases. Gastroenterology 99 (1990) 863-875
36. Gisbert J., and Pajares J. Helicobacter pylori therapy: first-line options and rescue regimen. Dig Dis 19 (2001) 134-143
37. Kuipers E., Kusters J., and Blaser M. Clinical approach to the Helicobacter pylori-positive patient (2002), Raven Press, New York
38. Go M. Treatment and management of Helicobacter pylori infection. Curr Gastroenterol Rep 4 (2002) 471-477
39. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16 (2002) 167-180
40. de Boer W., and Tytgat G. Regular review: treatment of Helicobacter pylori infection. BMJ 320 (2000) 31-34
41. Vergara M., Vallve M., Gisbert J., and Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 18 (2003) 647-654
42. Della Monica P., Lavagna A., Masoero G., Lombardo L., Crocella L., and Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 16 (2002) 1269-1275
43. Fischbach L., Goodman K., Feldman M., and Aragaki C. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 31 (2002) 128-139
44. Gisbert J., and Pajares J. Treatment of Helicobacter pylori eradication failures. Curr Treat Options Gastroenterol 6 (2003) 147-156
45. Thijs J., Van Zwet A., Thijs W., Van der Wouden E., and Kooy A. One-week triple therapy with omeprazole, amoxycillin and tinidazole for Helicobacter pylori infection: the significance of imidazole resistance. Aliment Pharmacol Ther 11 (1997) 305-309
46. Glupczynski Y., Megraud F., Lopez-Brea M., and Andersen L. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 20 (2001) 820-823
47. Meyer J., Silliman N., Wang W., et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 136 (2002) 13-24
48. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 11 suppl 1 (1997) 43-53
49. Wang G., and Taylor D. Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 42 (1998) 1952-1958
50. Fallone C. Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada. Can J Gastroenterol 14 (2000) 879-882
51. Mendonca S., Ecclissato C., Sartori M., et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 5 (2000) 79-83
52. Torres J., Camorlinga-Ponce M., Perez-Perez G., et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 39 (2001) 2677-2680
53. Vasquez A., Valdez Y., Gilman R., et al. Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. The Gastrointestinal Physiology Working Group of Universidad Peruana Cayetano Heredia and the Johns Hopkins University. J Clin Microbiol 34 (1996) 1232-1234
54. Ecclissato C., Marchioretto M., Mendonca S., et al. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter 7 (2002) 53-59
55. Dore M., Osato M., Realdi G., Mura I., Graham D., and Sepulveda A. Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother 43 (1999) 47-54
56. Dailidiene D., Bertoli M., Miciuleviciene J., et al. Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother 46 (2002) 3940-3946
57. Wu H., Shi X., Wang H., and Liu J. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother 46 (2000) 121-123
58. Kist M., and Glocker E. ResiNet - a nationwide German sentinel study for surveillance and analysis of antimicrobial resistance in Helicobacter pylori. Eurosurveillance 9 (2004) 44-46
59. Debets-Ossenkopp Y., Herscheid A., Pot R., Kuipers E., Kusters J., and Vandenbroucke-Grauls C. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in the Netherlands. J Antimicrob Chemother 43 (1999) 511-515
60. Moore R., Beckthold B., Wong S., Kureishi A., and Bryan L. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 39 (1995) 107-111
61. Heep M., Kist M., Strobel S., Beck D., and Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 19 (2000) 538-541
62. Tankovic J., Lascols C., Sculo Q., Petit J., and Soussy C. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 47 (2003) 3942-3944
63. Kwon D., Lee M., Kim J., et al. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 45 (2001) 306-308
64. van der Wouden E., Thijs J., van Zwet A., Sluiter W., and Kleibeuker J. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 94 (1999) 1751-1759
65. Laheij R., Rossum L., Jansen J., Straatman H., and Verbeek A. Evaluation of treatment regimens to cure Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 13 (1999) 857-864
66. Houben M., van de Beek D., Hensen E., Craen A., Rauws E., and Tytgat G. A systematic review of Helicobacter pylori eradication therapy-the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 13 (1999) 1047-1055
67. Megraud F., and Doermann H. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 43 suppl 1 (1998) S61-S65
68. Alarcon T., Domingo D., and Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 12 (1999) 19-26
69. Megraud F. Helicobacter pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53 (2004) 1374-1384
70. Van Der Wouden E., Thijs J., Van Zwet A., and Kleibeuker J. Review article: nitroimidazole resistance in Helicobacter pylori. Aliment Pharmacol Ther 14 (2000) 7-14
71. Xia H., Keane C., Beattie S., and O'Morain C. Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother 38 (1994) 2357-2361
72. Dore M., Leandro G., Realdi G., Sepulveda A., and Graham D. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 45 (2000) 68-76
73. Dore M., Kwon D., Sepulveda A., Graham D., and Realdi G. Stable amoxicillin resistance in Helicobacter pylori. Helicobacter 6 (2001) 79
74. Realdi G., Dore M., Piana A., et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 4 (1999) 106-112
75. Gomez-Lus R. Evolution of bacterial resistance to antibiotics during the last three decades. Int Microbiol 1 (1998) 279-284
76. Smeets L., Arents N., van Zwet A., et al. Molecular patchwork: chromosomal recombination between two Helicobacter pylori strains during natural colonization. Infect Immun 71 (2003) 2907-2910
77. Sisson G., Jeong J., Goodwin A., et al. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H pylori RdxA(+) (nitroreductase) gene. J Bacteriol 182 (2000) 5091-5096
78. Jenks P., and Edwards D. Metronidazole resistance in Helicobacter pylori. Int J Antimicrob Agents 19 (2002) 1-7
79. Alm R., Ling L., Moir D., et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397 (1999) 176-180
80. Tomb J., White O., Kerlavage A., et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388 (1997) 539-547
81. Goodwin A., Kersulyte D., Sisson G., Veldhuyzen van Zanten S., Berg D., and Hoffman P. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol 28 (1998) 383-393
82. Jeong J., Mukhopadhyay A., Dailidiene D., et al. Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level metronidazole resistance in Helicobacter pylori. J Bacteriol 182 (2000) 5082-5090
83. Kwon D., El Zaatari F., Kato M., et al. Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob Agents Chemother 44 (2000) 2133-2142
84. Kwon D., Kato M., El Zaatari F., Osato M., and Graham D. Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistant Helicobacter pylori ATCC43504 and its involvement in metronidazole resistance. FEMS Microbiol Lett 188 (2000) 197-202
85. Albert T., Dailidiene D., Dailide G., et al. Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori. Nat Methods 2 (2005) 951-953
86. Tankovic J., Lamarque D., Delchier J., Soussy C., Labigne A., and Jenks P. Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori. Antimicrob Agents Chemother 44 (2000) 608-613
87. Peters D., and Clissold S. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 44 (1992) 117-164
88. Vester B., and Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 45 (2001) 1-12
89. Versalovic J., Shortridge D., Kibler K., et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 40 (1996) 477-480
90. Stone G., Shortridge D., Versalovic J., et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 41 (1997) 712-714
91. Occhialini A., Urdaci M., Doucet-Populaire F., Bebear C., Lamouliatte H., and Megraud F. Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 41 (1997) 2724-2728
92. van Doorn L., Debets-Ossenkopp Y., Marais A., et al. Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrob Agents Chemother 43 (1999) 1779-1782
93. Garcia-Arata M., Baquero F., de Rafael L., et al. Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. Antimicrob Agents Chemother 43 (1999) 374-376
94. Fontana C., Favaro M., Minelli S., et al. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob Agents Chemother 46 (2002) 3765-3769
95. Hsieh P., Yang J., Lin J., and Wang J. Molecular mechanisms of clarithromycin resistance in Helicobacter pylori. J Formos Med Assoc 97 (1998) 445-452
96. Hulten K., Gibreel A., Skold O., and Engstrand L. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob Agents Chemother 41 (1997) 2550-2553
97. Hao Q., Li Y., Zhang Z., Liu Y., and Gao H. New mutation points in 23S rRNA gene associated with Helicobacter pylori resistance to clarithromycin in northeast China. World J Gastroenterol 10 (2004) 1075-1077
98. Kim K., Kang J., Eun C., Han D., and Choi T. Mutations in the 23S rRNA gene of Helicobacter pylori associated with clarithromycin resistance. J Korean Med Sci 17 (2002) 599-603
99. Toracchio S., Aceto G., Mariani-Costantini R., Battista P., and Marzio L. Identification of a novel mutation affecting fomain V of the 23S rRNA gene in Helicobacter pylori. Helicobacter 9 (2004) 396-399
100. Nakamura M., Spiller R., Barrett D., et al. Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter 8 (2003) 294-299
101. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 32 (2001) 1085-1089
102. van Zwet A., Vandenbroucke-Grauls C., Thijs J., et al. Stable amoxicillin resistance in Helicobacter pylori. Lancet 352 (1998) 1595
103. Dore M., Graham D., and Sepulveda A. Different penicillin-binding protein profiles in amoxicillin-resistant Helicobacter pylori. Helicobacter 4 (1999) 154-161
104. Kwon D., Dore M., Kim J., et al. High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori. Antimicrob Agents Chemother 47 (2003) 2169-2178
105. Okamoto T., Yoshiyama H., Nakazawa T., et al. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J Antimicrob Chemother 50 (2002) 849-856
106. Gerrits M., Schuijffel D., van Zwet A., Kuipers E., Vandenbroucke-Grauls C., and Kusters J. Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob Agents Chemother 46 (2002) 2229-2233
107. Gerrits M., Godoy A., Kuipers E., et al. Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori. Helicobacter 11 (2006) 181-187
108. DeLoney C., and Schiller N. Characterization of an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob Agents Chemother 44 (2000) 3368-3373
109. Brodersen D., Clemons Jr. W., Carter A., Morgan-Warren R., Wimberly B., and Ramakrishnan V. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 103 (2000) 1143-1154
110. Chopra I., and Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65 (2001) 232-260
111. Bina J., Alm R., Uria-Nickelsen M., Thomas S., Trust T., and Hancock R. Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob Agents Chemother 44 (2000) 248-254
112. Gerrits M., de Zoete M., Arents N., Kuipers E., and Kusters J. 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 46 (2002) 2996-3000
113. Trieber C., and Taylor D. Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J Bacteriol 184 (2002) 2131-2140
114. Gerrits M., Berning M., van Vliet A., Kuipers E., and Kusters J. Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 47 (2003) 2984-2986
115. Glocker E., Berning M., Gerrits M., Kusters J., and Kist M. Real-time PCR screening for 16S rRNA mutations associated with resistance to tetracycline in Helicobacter pylori. Antimicrob Agents Chemother 49 (2005) 3166-3170
116. Wu J., Kim J., Reddy R., Wang W., Graham D., and Kwon D. Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob Agents Chemother 49 (2005) 578-583
117. Ribeiro M., Gerrits M., Benvengo Y., et al. Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP. FEMS Immunol Med Microbiol 40 (2004) 57-61
118. Heep M., Rieger U., Beck D., and Lehn N. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 44 (2000) 1075-1077
119. Reece R., and Maxwell A. DNA gyrase: structure and function. Crit Rev Biochem Mol Biol 26 (1991) 335-375
120. Kim J., Kim J., Kim N., Jung H., and Song I. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 56 (2005) 965-967
121. Kunin C. Antimicrobial activity of rifabutin. Clin Infect Dis 22 suppl 1 (1996) S3-S13
122. Heep M., Lehn N., Brandstatter B., Rieger U., Senzenberger S., and Wehrl W. Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 21 (2002) 143-145
123. NCCLS. National Committe for Clinical Laboratory Standards: performance standards for antimicrobial susceptibility testing. Approved standard M7-A5, informational supplement M100S10 (2002), NCCLS, Wayne, PA, USA
124. Megraud F., Lehn N., Lind T., et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 43 (1999) 2747-2752
125. van der Wouden E., de Jong A., Thijs J., Kleibeuker J., and van Zwet A. Subpopulations of Helicobacter pylori are responsible for discrepancies in the outcome of nitroimidazole susceptibility testing. Antimicrob Agents Chemother 43 (1999) 1484-1486
126. Versalovic J., Osato M., Spakovsky K., et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 40 (1997) 283-286
127. Glocker E., and Kist M. Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J Clin Microbiol 42 (2004) 2241-2246
128. Fontana C., Favaro M., Pietroiusti A., Pistoia E., Galante A., and Favalli C. Detection of clarithromycin-resistant Helicobacter pylori in stool samples. J Clin Microbiol 41 (2003) 3636-3640
129. Schabereiter-Gurtner C., Hirschl A., Dragosics B., et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J Clin Microbiol 42 (2004) 4512-4518
130. Alarcon T., Domingo D., Prieto N., and Lopez-Brea M. PCR using 3′-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates. J Clin Microbiol 38 (2000) 923-925
131. Pina M., Occhialini A., Monteiro L., Doermann H., and Megraud F. Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase. J Clin Microbiol 36 (1998) 3285-3290
132. Maeda S., Yoshida H., Matsunaga H., et al. Detection of clarithromycin-resistant Helicobacter pylori strains by a preferential homoduplex formation assay. J Clin Microbiol 38 (2000) 210-214
133. Gibson J., Saunders N., Burke B., and Owen R. Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. J Clin Microbiol 37 (1999) 3746-3748
134. Oleastro M., Menard A., Santos A., et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol 41 (2003) 397-402
135. Trebesius K., Panthel K., Strobel S., et al. Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Gut 46 (2000) 608-614
136. Prinz C., Hafsi N., and Voland P. Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination. Trends Microbiol 11 (2003) 134-138
137. Michetti P., Kreiss C., Kotloff K., et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116 (1999) 804-812
138. Banerjee S., Medina-Fatimi A., Nichols R., et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 51 (2002) 634-640
139. Dunn B., Vakil N., Schneider B., et al. Localization of Helicobacter pylori urease and heat shock protein in human gastric biopsies. Infect Immun 65 (1997) 1181-1188
140. Hase K., Murakami M., Iimura M., et al. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. Gastroenterology 125 (2003) 1613-1625
141. Bajaj-Elliott M., Fedeli P., Smith G., et al. Modulation of host antimicrobial peptide (beta-defensins 1 and 2) expression during gastritis. Gut 51 (2002) 356-361
142. Iwahori A., Hirota Y., Sampe R., Miyano S., and Numao N. Synthesis of reversed magainin 2 analogs enhanced antibacterial activity. Biol Pharm Bull 20 (1997) 267-270
143. Kamysz W., Okroj M., and Lukasiak J. Novel properties of antimicrobial peptides. Acta Biochim Pol 50 (2003) 461-469
144. Stojiljkovic I., Evavold B., and Kumar V. Antimicrobial properties of porphyrins. Expert Opin Investig Drugs 10 (2001) 309-320
145. Bergonzelli G., Donnicola D., Porta N., and Corthesy-Theulaz I. Essential oils as components of a diet-based approach to management of helicobacter infection. Antimicrob Agents Chemother 47 (2003) 3240-3246
146. Ohno T., Kita M., Yamaoka Y., et al. Antimicrobial activity of essential oils against Helicobacter pylori. Helicobacter 8 (2003) 207-215
147. Sgouras D., Maragkoudakis P., Petraki K., et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 70 (2004) 518-526
148. Collado M., Gonzalez A., Gonzalez R., Hernandez M., Ferrus M., and Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by bifidobacterium against Helicobacter pylori. Int J Antimicrob Agents 25 (2005) 385-391